News | January 03, 2023
Blacksmith announces merger with Forge Therapeutics
To create leading company developing medicines targeting metalloenzymes
To create leading company developing medicines targeting metalloenzymes
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
Greenko ZeroC will supply Carbon Free Energy and enable Green Hydrogen along with its various chemical derivatives.
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
All claims against the company in the litigation have now been dismissed.
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Miravo to remain a Canadian controlled and operated company following closing of the transaction
Subscribe To Our Newsletter & Stay Updated
